According to the European Society for Medical Oncology guidelines, the standard first-line treatment in these patients includes doublet (fluoropyrimidines plus oxaliplatin or irinotecan) or triplet chemotherapy (fluoropyrimidines, oxaliplatin and irinotecan) alone or in combination with monoclonal antibodies against epidermal growth factor receptor (EGFR; cetuximab or panitumumab) or vascular endothelial growth factor A (VEGF-A; bevacizumab), depending on the tumor RAS/BRAF mutational status [1]. The gene discussed is VEGFA; the disease is neoplasm.